A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Obinutuzumab in Adolescent Patients With Active Class III Or IV Lupus Nephritis

Back to trials